Peripheral arterial disease and diabetes

Česká verzia

Authors: R. Malý ¹; V. Chovanec ²
Authors place of work: Subkatedra angiologie I. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Jan Vojáček, DrSc., FESC, FACC2Radiologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Pavel Eliáš, CSc. ¹
Published in the journal: Vnitř Lék 2010; 56(4): 341-346
Category: 11th National Diabetes Symposium "Diabetes and Angiology", Hradec Kralove, 5 to 6 June 2009

Summary

Peripheral arterial disease (PAD) is a disease characterised by narrowing and blockade of peripheral arteries, usually based on underlying obliterating atherosclerosis. According to the results of large epidemiological studies, the risk of PAD in patients with diabetes mePADtus (DM) is fourfold higher compared to non‑diabetic population. Patients with DM and PAD have a high risk of cardiovascular morbidity and mortality. Diabetes worsens the prognosis of patients with PAD; the onset of PAD in diabetics occurs at an earlier age, the course is faster than in non‑diabetic patients and the disease is often diagnosed at its advanced stages. All these factors reduce the likelihood of revascularisation in DM patients with PAD. A range of factors (higher age, arterial hypertension, smoking, obesity, hyperfibrinogenaemia, insulin resistance etc.) contribute to the development of PAD in DM. Diabetes control is an independent risk factor of PAD as every 1% increase of hemoglobin A1C is associated with 28% increase of PAD. There are different clinical signs of PAD in diabetic and non‑diabetic patients. In addition to the history of claudications, PAD diagnostic criteria include the presence of murmur over the large arteries, signs of chronic ischemia on the skin and distal ulcerations and gangrene. Among the imaging techniques, non‑invasive investigations including Doppler pressure measurement, ankle brachial pressure index, color duplex ultrasonography, plethysmography, transcutaneous tension measurement, MR and CT angiography are preferred. Ankle brachial pressure index measurement is the easiest and the main investigation technique. The key principles of PAD treatment in diabetic patients include modification of risk factors, pharmacotherapy and revascularisation interventions aimed at improving clinical signs and prevention of cardiovascular morbidity and mortality. Antiplatelet treatment may prevent PAD progression and reduce cardiovascular events in DM patients. Early diagnosis of PAD in DM patients, rigorous prevention and aggressive management of the risk factors may significantly impact on the high incidence of amputations and decrease cardiovascular morbidity and mortality.

Key words:
diabetes mellitus – peripheral arterial disease – ankle brachial index – risk factors – critical limb ischemia – treatment

Zdroje

1. Norgren L, Hiatt WR, Dormandy JA et al. Inter‑ Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1– S75.

2. Jude EB. Intermittent claudication in the patient with diabetes. Br J Diabetes Vasc Dis 2004; 4: 238– 242.

3. Jude EB, Oyibo SO, Chalmers N et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24: 1433– 1437.

4. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26: 3333– 3341.

5. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13– 18.

6. Hirsch AT, Criqui MH, Treat‑ Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317– 1324.

7. Melton LJ 3rd, Macken KM, Palumbo PJ et al. Incidence and prevalence of clinical peripheral vascular disease in a population‑based cohort of diabetic patients. Diabetes Care 1980; 3: 650– 654.

8. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes‑ a review. Diabet Med 2010; 27: 4– 14.

9. Walters DP, Gatling W, Mullee MA et al. The prevalence, detection, and epidemiological correlates of peripheral vascular disease: a comparison of diabetic and non‑diabetic subjects in an English community. Diabet Med 1992; 9: 710– 715.

10. Adler AI, Stevens RJ, Neil A et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894– 899.

11. Hirsch AT, Hiatt WR. PAD awareness, risk, and treatment: new resources for survival – the USA PARTNERS program. Vasc Med 2001; 6 (Suppl 3): 9– 12.

12. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new‑onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003; 26: 491– 494.

13. Dolan NC, Liu K, Criqui MH et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002; 25: 113– 120.

14. Karetová D, Staněk F. Angiologie pro praxi. Praha: Maxdorf 2001.

15. Resnick HE, Lindsay RS, McDermott MM et al. Relationship of high and low ankle brachial index to all‑cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 17; 109: 733– 739.

16. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47: 921– 929.

17. Aboyans V, Ho E, Denenberg JO et al. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. J Vasc Surg 2008; 48: 1197– 1203.

18. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608– 1621.

19. Tsai JC, Chan P, Wang CH et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med 2002; 252: 448– 455.

20. Holman RR, Paul SK, Bethel MA et al. 10‑year follow‑up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577– 1589.

21. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists’ Collaboration. Br Med J (Clin Res Ed) 1988; 296: 320– 331.

22. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329– 1339.

23. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3: 117– 138.

24. Šmahelová A. A role of diabetologist in management of infections in diabetics. Vnitř Lék 2006; 52: 443– 445.

25. Procházka V, Gumulec J, Chmelová J et al. Autologous bone marrow stem cell transplantation in patients with end‑stage chronical critical limb ischemia and diabetic foot. Vnitř Lék 2009; 55: 173– 178.

26. Talapková R, Hudeček J, Sinák I et al. The salvage of ischaemic limb by therapeutical angiogenesis. Vnitř Lék 2009; 55: 179– 183.

27. Bláha M, Rencová E, Bláha V et al. Rheopheresis in vascular diseases. Int J Artif Organs 2008; 31: 456– 457.

28. Weiss N. Lipid apheresis and rheopheresis for treatment of peripheral arterial disease. Atheroscler Suppl 2009; 10: 62– 69.

29. Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg 2010; 51: 230– 241.

30. Maca TH, Ahmadi R, Derfler K et al. Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in type 2 diabetic patients. Diabet Med 2002; 19: 300– 306.